Saeki N - Search Results

1

Selection of chemotherapy for glioblastoma expressing O(6)-methylguanine-DNA methyltransferase.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Oide T, Tanizawa T, Nakatani Y, Saeki N, Fujimoto S. Iwadate Y, et al. Among authors: saeki n. Exp Ther Med. 2010 Jan;1(1):53-57. doi: 10.3892/etm_00000009. Epub 2010 Jan 1. Exp Ther Med. 2010. PMID: 23136592 Free PMC article.

2

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N. Iwadate Y, et al. Among authors: saeki n. J Neurooncol. 2011 May;102(3):443-9. doi: 10.1007/s11060-010-0340-4. Epub 2010 Aug 19. J Neurooncol. 2011. PMID: 20721680

3

Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.

Iwadate Y, Matsutani T, Shinozaki N, Saeki N. Iwadate Y, et al. Among authors: saeki n. Anticancer Res. 2011 Dec;31(12):4475-9. Anticancer Res. 2011. PMID: 22199318

4

Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma.

Iwadate Y, Matsutani T, Hirono S, Shinozaki N, Saeki N. Iwadate Y, et al. Among authors: saeki n. J Neurooncol. 2016 Aug;129(1):101-7. doi: 10.1007/s11060-016-2145-6. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193555

5

The Pluripotent Stem-Cell Marker Alkaline Phosphatase is Highly Expressed in Refractory Glioblastoma with DNA Hypomethylation.

Iwadate Y, Suganami A, Tamura Y, Matsutani T, Hirono S, Shinozaki N, Hiwasa T, Takiguchi M, Saeki N. Iwadate Y, et al. Among authors: saeki n. Neurosurgery. 2017 Feb 1;80(2):248-256. doi: 10.1093/neuros/nyw026. Neurosurgery. 2017. PMID: 28173571

6

Akt/protein kinase B overexpression as an accurate prognostic marker in adult diffuse astrocytoma.

Matsutani T, Nagai Y, Mine S, Murai H, Saeki N, Iwadate Y. Matsutani T, et al. Among authors: saeki n. Acta Neurochir (Wien). 2009 Mar;151(3):263-8; discussion 268. doi: 10.1007/s00701-009-0199-3. Epub 2009 Feb 25. Acta Neurochir (Wien). 2009. PMID: 19240976

7

Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.

Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, Iwadate Y. Shinozaki N, et al. Among authors: saeki n. J Neurosurg. 2011 Jun;114(6):1640-7. doi: 10.3171/2010.11.JNS10553. Epub 2011 Jan 7. J Neurosurg. 2011. PMID: 21214332

8

Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.

Matsutani T, Hiwasa T, Takiguchi M, Oide T, Kunimatsu M, Saeki N, Iwadate Y. Matsutani T, et al. Among authors: saeki n. J Exp Clin Cancer Res. 2012 Oct 11;31(1):85. doi: 10.1186/1756-9966-31-85. J Exp Clin Cancer Res. 2012. PMID: 23050879 Free PMC article.

9

Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.

Iwadate Y, Suganami A, Ikegami S, Shinozaki N, Matsutani T, Tamura Y, Saeki N, Yamanaka R. Iwadate Y, et al. Among authors: saeki n. J Neurooncol. 2014 Apr;117(2):261-8. doi: 10.1007/s11060-014-1379-4. Epub 2014 Feb 1. J Neurooncol. 2014. PMID: 24488444

10

IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.

Iwadate Y, Matsutani T, Hirono S, Ikegami S, Shinozaki N, Saeki N. Iwadate Y, et al. Among authors: saeki n. J Neurooncol. 2015 Sep;124(3):493-500. doi: 10.1007/s11060-015-1863-5. Epub 2015 Aug 5. J Neurooncol. 2015. PMID: 26243269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

384 results

Search Page

Filters